Friday, July 10, 2026

pharma · Colorectal Neoplasms · Borderline Resectable Pancreatic Adenocarcinoma

Zhejiang Rongyao Biotech

Zhejiang Rongyao Biotech trial registry — 2 ClinicalTrials.gov studies with program phase, status, and indication context.

CN HQ
1999 Founded
5 Employees
NMPA registrant Type
Company details
Status
Public
HQ
CN
Founded
1999
Employees
5
Programs
2
Drugs
3
Patents
0
Intelligence · Clinical Trials

Zhejiang Rongyao Biotech clinical trials

Registry index of 2 ClinicalTrials.gov studies linked to Zhejiang Rongyao Biotech programs — each row shows trial ID, program name, phase, status, and indication.

Zhejiang Rongyao Biotech trial registry — 2 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

2 updates

Latest clinical program signals indexed for Zhejiang Rongyao Biotech.

  1. Cetuximab β;Fruquintinib; — Phase 2

    Clinical update
  2. HRS-4642+AG+Nimotuzumab — Phase 2

    Clinical update

Trial registry

2 studies